The remarkable contribution of immunization programs to public health is recognized by most people, including those who express vaccine hesitancy. Vaccine hesitancy often is predicated on the concern of an individual or family members regarding the risk of an adverse event following immunization. But for each licensed vaccine, the relative risk of an untoward event, such as contracting the disease, is greater among those who remain unvaccinated.1 Before US Food and Drug Administration (FDA) licensure, vaccine safety must be determined by demonstration that the benefit from disease prevention exceeds the risk of adverse reactions associated with the vaccine. However, this assessment is not always straightforward and the societal perspective of regulatory and advisory bodies may conflict with the individual perspective of the patient or parent. Experience with rotavirus vaccines and, more recently, the dengue virus vaccine provides insight into the complexity of this assessment.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Meissner HC. Complexity in Assessing the Benefit vs Risk of Vaccines: Experience With Rotavirus and Dengue Virus Vaccines. JAMA. 2019;322(19):1861–1862. doi:10.1001/jama.2019.16206
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: